The European Medicines Agency has announced that it is currently reviewing additional safety data on Acomplia and it will make an announcement on either 19th or 20th July regarding the future of Acomplia. New data has been submitted which appears to suggest that Acomplia has brought on suicidal thoughts in some patients being treated with the medication. Although we do not believe that Acomplia will be withdrawn from the market in Europe, this option cannot be ruled out. We do not recommend this medication for anyone with a history of major depression and this is likely to be the formal recommendation of the panel at the European Medicines Agency. Acomplia is currently only not recommended if someone is being treated for depression.
We will bring you more news on this item as soon as we have it.